St. Francis Medical Center, Baltimore, MD. The pricing committee meets every third Thursday.
On October 14th, 2024, a committee of seven people convened in a conference room on the 34th floor of a Midtown Manhattan office tower. No patients were present. No physicians. The agenda: finalize the 2025 formulary tier assignments for 47 specialty drugs — a decision that would determine, within weeks, what 38 million commercially insured Americans would pay for medications they had already been prescribed.
Chronicle obtained the meeting minutes through a whistleblower who attended as a junior analyst. What they reveal is not corruption — nothing so clean. What they reveal is a system designed to make accountability structurally impossible.
Key Finding
The Rebate Pass-Through Gap, 2019–2024
Source: CMS actuarial data, SEC filings, Chronicle analysis. N = 6 largest PBM contracts.
"The formulary is not a medical document. It's a negotiating position. The patients are the leverage."— Dr. Reginald Osei, Former CVS Health Medical Director, 2017–2022
The seven people in that conference room represented a single pharmacy benefit manager — one of three that together administer drug benefits for 270 million Americans. Their decisions are not subject to public comment, congressional oversight, or even disclosure to the health plans nominally paying them. The contracts that govern their behavior contain, routinely, provisions that prohibit the health plans from auditing the rebate calculations.
This is the mechanism. Not a conspiracy. A contract clause. And it has been renewed, every three years, by CFOs at every major insurer in America, because the alternative — transparency — would require explaining to shareholders why margins are lower than they could be.
The full investigation includes the unredacted meeting minutes, a complete analysis of 14 PBM contracts obtained through litigation discovery, interviews with 23 current and former industry executives, and a methodology appendix co-authored with researchers at the USC Schaeffer Center.
Read the Full InvestigationFree registration · No credit card required
Previous Investigations
The Chronicle Archive
The Formulary Architects
How three companies control which drugs 220 million Americans can afford.
The Staffing Agency Arbitrage
Travel nurse markups averaging 312% — and the hospital CFOs who quietly approve them.
CMS's Quiet Retreat
The rule change buried in 847 pages that shifted $14B in reimbursement risk to providers.
Vertical Integration's Hidden Tax
When UnitedHealth owns the doctor, the hospital, and the insurer, who negotiates?
The Prior Auth Machine
Algorithms deny 18% of claims on first submission. The appeal rate is 0.2%.
Biosimilar Winter
Congress passed the pathway. Fourteen years later, 94% of patients still can't access it.
The methodology behind the investigation.
We have been investigating the American healthcare system for twelve years. In that time, we have been cited in congressional testimony fourteen times, quoted in Supreme Court amicus briefs twice, and retracted zero findings.
Primary Source Reporting
Every investigation begins with a named source who was in the room. We do not publish based on documents alone. Every claim is triangulated against at least three independent sources before it goes to print.
Quantitative Methodology
Our data team conducts original analysis on CMS datasets, SEC filings, court records, and proprietary surveys. All models are peer-reviewed by academic partners before publication.
Right of Reply
Every named organization receives a detailed list of findings 10 business days before publication. Their responses — in full — are published in an appendix. We do not summarize rebuttals.
No Advertising
Chronicle is funded entirely by reader subscriptions and institutional licenses. We accept no advertising, sponsored content, or research funding from any organization we cover. Ever.
The Chronicle Archive
Nov 2025
Pharma
The Formulary Architects
How three pharmacy benefit managers control which drugs 220 million Americans can access — and the contract clauses that prevent anyone from auditing how.
Aug 2025
Hospitals
The Staffing Agency Arbitrage
Travel nurse markups averaging 312% — and the hospital CFOs who quietly approve them because the alternative is closing ICU beds.
Apr 2025
Policy
CMS's Quiet Retreat
The rule change buried in 847 pages of regulatory text that shifted $14 billion in reimbursement risk from Medicare to providers — and the comment period no one attended.
Dec 2024
Insurers
Vertical Integration's Hidden Tax
When the same holding company owns the physician practice, the hospital, the pharmacy, and the insurer, market rates become a fiction.
Sep 2024
Insurers
The Prior Auth Machine
Algorithms deny 18% of claims on first submission. The appeal rate is 0.2%. We obtained the vendor contract.
Jun 2024
Pharma
Biosimilar Winter
Congress passed the regulatory pathway in 2010. Fourteen years later, 94% of patients who could benefit still can't access it. Here is why.
Showing 6 of 84 investigations in the Chronicle archive.
Access Full Archive